92% — When will the FDA approve retatrutide (LY3437943)
Leader: Before Jan 1, 2029 at 92% · Kalshi 92% · 5 contracts · $128 volume · medium confidence
Updated 2026-08-24 05:34:01 UTC

Tracks the leading outcome in a winner-take-all prediction market set with 5 outcomes.

Why this matters:
Markets currently assign a 92% probability that the FDA will approve retatrutide (Eli Lilly's obesity and diabetes drug) by January 1, 2029. This reflects confidence in eventual approval, though the contract chain shows material uncertainty about timing—traders see only a 16% chance of approval before January 2027, suggesting the review process extends beyond near-term. The probability is elevated by retatrutide's clinical trial data and Lilly's development track record with similar GLP-1 compounds, but remains below certainty because regulatory outcomes are never guaranteed. FDA action timelines depend on submission completeness, any safety signals during review, and the agency's current workload. The most immediate resolution point would be a formal FDA decision or any major clinical or manufacturing disclosure that affects approval likelihood.

Key factors:
- Retatrutide has shown clinical efficacy in Phase 3 trials, but approval hinges on FDA's safety and manufacturing review standards, which can extend timelines unpredictably
- The 65-cent contract for approval by July 2027 suggests a base-case timeline of 12–18 months from now, implying submission may already be in progress or imminent
- No scheduled FDA decision date is publicly confirmed; a breakthrough designation or priority review status would accelerate approval odds materially
- Manufacturing scale-up or supply-chain constraints could delay launch even after regulatory clearance
- Competitive GLP-1 drug approvals and label expansions may influence FDA prioritization but do not directly determine retatrutide's path

Contracts:
- When will the FDA approve retatrutide (LY3437943)?: Before Jan 1, 2029 — 92¢ Kalshi $0 (weight 0%)
- When will the FDA approve retatrutide (LY3437943)?: Before Jul 1, 2028 — 88¢ Kalshi $0 (weight 0%)
- When will the FDA approve retatrutide (LY3437943)?: Before Jan 1, 2028 — 86¢ Kalshi $1 (weight 0%)
- When will the FDA approve retatrutide (LY3437943)?: Before Jul 1, 2027 — 40¢ Kalshi $6 (weight 5%)
- When will the FDA approve retatrutide (LY3437943)?: Before Jan 1, 2027 — 6¢ Kalshi $122 (weight 95%)

---

## Methodology

SimpleFunctions aggregates live YES-side prices from Kalshi and Polymarket contracts bound to this question. For binary topics the headline is the liquidity-weighted mid-price (weight = log(1 + 24h volume) × freshness, where freshness is 1.0 if updated <24h, 0.7 if <7d, 0.4 otherwise). For multi-outcome (winner-take-all) topics the headline is the current leader's price — disjoint outcomes are never arithmetically averaged. Snapshots refresh every 5 minutes during market hours.

## SF Signal

- SF Index, regime, and 30d Brier calibration are computed separately and surfaced at https://simplefunctions.dev/admin/calibration.
- No SimpleFunctions index / regime / calibration signal is bound to this topic yet — the headline above is market-derived only.

---

*Last verified: 2026-08-24T05:20:52.455Z*

By SimpleFunctions — https://simplefunctions.dev/

Cite as: "92% per prediction markets (SimpleFunctions, August 2026)"
Canonical: https://simplefunctions.dev/answer/fdaretatrutide-ret
Full data: https://simplefunctions.dev/api/public/query?q=When%20will%20the%20FDA%20approve%20retatrutide%20(LY3437943)
Provider: SimpleFunctions — https://simplefunctions.dev